We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Infectious Diseases Specialists on the Appropriateness of Antimicrobial Therapy in Emergency Wards (ATBREFEMERG)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01137864
First Posted: June 7, 2010
Last Update Posted: July 29, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Philippe LESPRIT, Henri Mondor University Hospital
  Purpose

CONTEXT: Antibiotics are frequently used in hospital but the appropriateness of prescriptions ranged between 25-50%. The intervention of infectious disease specialists (IDS) could improve the appropriateness of prescriptions and reduce their use. The impact of IDS has not been yet fully estimated using a randomized trial to compare the quality of care of patients who will benefit of the intervention.

OBJECTIVES: To show using a randomized trial that patients hospitalized in emergency wards with IDS advice will receive more appropriate antimicrobial therapy but less exposure to antibiotics, as compared to patients who will not receive IDS advice.

METHODS: Prospective randomized trial comparing antibiotic exposure and appropriateness of prescriptions in two groups of patients admitted in emergency wards:

Control group: antibiotic prescriptions will be initiated and managed by the attending physicians Intervention group: antibiotic prescriptions will be systematically evaluated by the IDS and changed if judged necessary by the attending physicians, following IDS' advice.

STUDY PROCESS: The study will took place in the emergency wards of 4 university hospitals. For each ward, the period of the study will be 2 x 4 weeks.Total duration of the study: 12 months.


Condition Intervention
Patients Under Antimicrobial Therapy Other: Infectious disease specialist advice

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Impact of Infectious Diseases Specialists on the Appropriateness of Antimicrobial Therapy in Emergency Wards: a Multicenter Randomized Controlled Trial.

Resource links provided by NLM:


Further study details as provided by Philippe LESPRIT, Henri Mondor University Hospital:

Primary Outcome Measures:
  • Appropriateness of antimicrobial therapy [ Time Frame: Between days 1 and 3 ]
    Appropriateness of antimicrobial therapy will be evaluated at the end of hospitalization in emergency ward (on average, between days 1 and 3).


Secondary Outcome Measures:
  • Clinical impact [ Time Frame: Between days 1 and 3 ]
    Length of hospitalization; clinical outcome: resolution of infection; in hospital mortality. These end points will be evaluated at the end of hospitalization in emergency ward (on average, between days 1 and 3).

  • Antibiotic exposure [ Time Frame: 14 days ]

    Antibiotic exposure will be evaluated at the time of discharge from emergency ward (on average, between days 1 and 3) using the following parameters:

    number of days of therapy/numbers of days of hospitalization; defined daily doses of antibiotic/number of days of hospitalization



Enrollment: 255
Study Start Date: June 2010
Study Completion Date: October 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Infectious disease specialist advice
Patients receiving the intervention (infectious disease specialist advice)
Other: Infectious disease specialist advice
Indication, choice, dosing and duration of antimicrobial therapy
No Intervention: Control
Patients not receiving infectious disease specialist advice

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults Hospitalized in emergency wards Receiving antimicrobial therapy for active infection or prolonged surgical prophylaxis Therapy prescribed by the attending ward physician

Exclusion Criteria:

  • Patients receiving antimicrobial therapy not prescribed by the attending ward physician
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01137864


Locations
France
Henri Mondor University Hospital
Créteil, France, 94010
Sponsors and Collaborators
Henri Mondor University Hospital
Investigators
Principal Investigator: Philippe Lesprit, MD Assistance Publique - Hôpitaux de Paris
  More Information

Responsible Party: Philippe LESPRIT, Dr Philippe LESPRIT, Henri Mondor University Hospital
ClinicalTrials.gov Identifier: NCT01137864     History of Changes
Other Study ID Numbers: PREQHOS 08023b
First Submitted: June 1, 2010
First Posted: June 7, 2010
Last Update Posted: July 29, 2014
Last Verified: July 2014

Keywords provided by Philippe LESPRIT, Henri Mondor University Hospital:
Emergency wards
Hospitalization
Adults
Antimicrobial therapy

Additional relevant MeSH terms:
Emergencies
Communicable Diseases
Infection
Disease Attributes
Pathologic Processes
Anti-Infective Agents
Anti-Bacterial Agents